Merck's CAPVAXIVE Added To Ontario's Publicly Funded Adult Immunization Program

Merck (NYSE: MRK) announced that Ontario has added its CAPVAXIVE® vaccine to the publicly funded adult immunization program, enhancing access for eligible older adults. CAPVAXIVE® is designed to prevent invasive pneumococcal disease (IPD) in adults aged 18 and older. Surveillance data from 2019 to 2023 indicates that the serotypes included in CAPVAXIVE® accounted for approximately 65% of IPD cases in adults aged 18–49, 74% in those aged 50–64, and 80% in adults aged 65 and older.